Anavex Life Sciences Corp. (NASDAQ:AVXL) Receives Average Rating of “Hold” from Brokerages

Posted by Geri Gentry on Sep 6th, 2026

Anavex Life Sciences Corp. (NASDAQ:AVXL – Get Free Report) has earned an average rating of “Hold” from the five ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have issued a buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $21.3333.

Separately, Weiss Ratings lowered shares of Anavex Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th.

Check Out Our Latest Stock Report on Anavex Life Sciences

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. State of Wyoming purchased a new position in shares of Anavex Life Sciences in the 2nd quarter valued at approximately $26,000. Yukon Wealth Management Inc. purchased a new stake in Anavex Life Sciences in the second quarter worth $36,000. Quarry LP bought a new position in Anavex Life Sciences in the third quarter worth $36,000. Advisory Alpha LLC bought a new position in Anavex Life Sciences in the fourth quarter worth $44,000. Finally, Aigen Investment Management LP purchased a new position in Anavex Life Sciences during the fourth quarter valued at $44,000. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Stock Up 0.4%

Anavex Life Sciences stock opened at $2.86 on Friday. The firm has a fifty day simple moving average of $2.86 and a two-hundred day simple moving average of $3.20. Anavex Life Sciences has a twelve month low of $2.26 and a twelve month high of $10.40. The company has a market capitalization of $265.12 million, a PE ratio of -19.07 and a beta of 1.14.

Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) last released its earnings results on Tuesday, August 25th. The biotechnology company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.16.

About Anavex Life Sciences

(Get Free Report)

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.